Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma

Although two newly launched monoclonal antibodies (mAbs), elotuzumab and daratumumab, performed well in patients with relapsed or relapsed/refractory multiple myeloma (RRMM), their efficacy and safety remain uncertain. We therefore performed a systematic review and meta-analysis of the most recent c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tiantian, Wang, Sen, Lin, Tengfei, Xie, Jingmei, Zhao, Lina, Liang, Zhuoru, Li, Yangqiu, Jiang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464929/
https://www.ncbi.nlm.nih.gov/pubmed/28454113
http://dx.doi.org/10.18632/oncotarget.16987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464929/
https://www.ncbi.nlm.nih.gov/pubmed/28454113
http://dx.doi.org/10.18632/oncotarget.16987

Ejemplares similares